Daily Stock Analysis, ACAD, ACADIA Pharmaceuticals Inc, priceseries

ACADIA Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
39.03
Close
39.28
High
39.32
Low
38.56
Previous Close
39.22
Daily Price Gain
0.06
YTD High
40.49
YTD High Date
Feb 16, 2017
YTD Low
28.53
YTD Low Date
Jan 3, 2017
YTD Price Change
10.51
YTD Gain
36.53%
52 Week High
42.49
52 Week High Date
Jun 9, 2016
52 Week Low
17.02
52 Week Low Date
Mar 1, 2016
52 Week Price Change
19.16
52 Week Gain
95.23%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 7. 2015
32.84
Apr 27. 2015
37.16
14 Trading Days
13.16%
Link
LONG
May 8. 2015
37.94
Jun 8. 2015
41.11
20 Trading Days
8.36%
Link
LONG
Jul 9. 2015
42.18
Jul 27. 2015
47.54
12 Trading Days
12.72%
Link
LONG
Oct 27. 2015
34.09
Nov 6. 2015
37.47
8 Trading Days
9.91%
Link
LONG
Mar 28. 2016
23.81
Apr 26. 2016
33.16
21 Trading Days
39.28%
Link
LONG
May 16. 2016
30.03
Jun 13. 2016
37.74
19 Trading Days
25.69%
Link
LONG
Jul 20. 2016
34.65
Aug 4. 2016
36.54
11 Trading Days
5.45%
Link
LONG
Nov 7. 2016
22.99
Nov 22. 2016
27.41
11 Trading Days
19.24%
Link
LONG
Dec 22. 2016
27.67
Jan 11. 2017
30.04
12 Trading Days
8.57%
Link
Company Information
Stock Symbol
ACAD
Exchange
NasdaqGS
Company URL
http://www.acadia-pharm.com
Company Phone
858-558-2871
CEO
Stephen R. Davis
Headquarters
California
Business Address
3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO, CA 92130
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001070494
About

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders.

Description

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease psychosis and the Phase II trial for the treatment of schizophrenia, as well as is in Phase II study for the treatment of Alzheimer's disease psychosis. It also has clinical-stage programs for glaucoma and, in collaboration with Allergan, Inc., for chronic pain. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.